Manal F. Abdelmalek, MD, MPH is a tenured Professor of Medicine in the Division of Gastroenterology and Hepatology and Director of the Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Research Program at Duke University. She received training in Internal Medicine, Gastroenterology and Hepatology at the Mayo Clinic, Rochester, MN and obtained an MPH degree with an emphasis in epidemiology, public health, and clinical investigation at the University of Florida, Gainesville, Florida. Since first reporting on nonalcoholic steatohepatitis (NASH) as a cause of cryptogenic cirrhosis nearly 25 years ago, her clinical and research area of interest has been in the field of NAFLD, its associated risk factors for disease acquisition and progression, and the discovery of novel approaches to treatment. She has expertise in the design and conduct of clinical trials in NAFLD/ NASH including investigator-initiated, industry-sponsored, and NIH-funded clinical studies evaluating new therapies and biomarkers for NAFLD and NASH. She collaborates extensively to translate new compounds to first-in-man clinical studies and translate clinic-to-bench and bench-to-clinic research to define pathogenic mechanisms underlying NAFLD acquisition and progression. She is a key opinion leader in the field of NASH Therapeutics, a member of the Liver Forum, and advisor/ consultant to many industries, FDA, and biomarker development companies in the area of diagnostics and therapeutics for NASH. Dr. Abdelmalek is a Fellow of American College of Physicians, American College of Gastroenterology, and American Association for the Study of Liver Disease. She is a standing member of the NASH Clinical Research Network (NASH CRN) for the past 15 years. She has over 200 publications authored publications in the field of liver disease, the majority of which are in the area of NAFLD/NASH.
